The US FDA has granted a priority review to Johnson & Johnson’s Invokana in diabetic kidney disease, signposting an end to a 20-year drought on new therapies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,